Skip to content

Study · Not a test of the peptide alone · 2015

2 results

Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells.

Soo JS, Ng CH, Tan SH, Malik RA, Teh YC, Tan BS, Ho GF, See MH, Taib NA, Yip CH, Chung FF, Hii LW, Teo SH, Leong CO

Apoptosis : an international journal on programmed cell death1 Oct 2015Cited by 50 (Europe PMC)

PMID26276035 (opens in a new tab)DOI10.1007/s10495-015-1158-5 (opens in a new tab)PepBankPUB-26276035
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, AICAR (acadesine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking AICAR (acadesine).

  1. 01LabNot a test of AICAR (acadesine) aloneIn vitro (cells)Efficacy outcome

    In non-stem breast cancer cells, AICAR did not synergize FEC chemotherapy.

    In plain wordsIn cells, AICAR did not strengthen FEC chemotherapy.

    Peptide
    AICAR (acadesine)
    Outcome
    No significant changeFEC synergy in non-stem cells
    Study

    n: not reported in source

    non-stem breast cancer cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    In this study, we demonstrated that metformin, but not other AMPK activators (e.g. AICAR and A-769662), synergizes 5-fluouracil, epirubicin, and cyclophosphamide (FEC) combination chemotherapy in non-stem breast cancer cells and breast cancer stem cells.

    In this study, AICAR (acadesine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking AICAR (acadesine).

  2. 02LabNot a test of AICAR (acadesine) aloneIn vitro (cells)Efficacy outcome

    In breast cancer stem cells, AICAR did not synergize FEC chemotherapy.

    In plain wordsIn cells, AICAR did not strengthen FEC chemotherapy in breast cancer stem cells.

    Peptide
    AICAR (acadesine)
    Outcome
    No significant changeFEC synergy in stem cells
    Study

    n: not reported in source

    breast cancer stem cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    In this study, we demonstrated that metformin, but not other AMPK activators (e.g. AICAR and A-769662), synergizes 5-fluouracil, epirubicin, and cyclophosphamide (FEC) combination chemotherapy in non-stem breast cancer cells and breast cancer stem cells.

    In this study, AICAR (acadesine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking AICAR (acadesine).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.